Tony Coles, M.D.
Chairman and Chief Executive Officer, Yumanity Therapeutics
Dr. Tony Coles is a founding investor and the Chairman and Chief Executive Officer of Yumanity Therapeutics, a Cambridge, Massachusetts-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis (ALS). He also serves as Chairman and Chief Executive Officer of TRATE Enterprises, LLC, a privately held company.
Previously, Tony was Chairman and Chief Executive Officer of Onyx Pharmaceuticals Inc., which was acquired by Amgen in late 2013. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the Board of Directors of NPS Pharmaceuticals Inc. Before joining NPS Pharmaceuticals in 2005, Tony was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Inc., and earlier, held a number of executive positions at Bristol-Myers Squibb Company and positions of increasing responsibility at Merck & Co. Inc.
Tony currently serves on the Board of Directors of McKesson Corporation and Regeneron and is a member of the Board of Trustees for Johns Hopkins University and Johns Hopkins Medicine. He is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the Board of Trustees for The Metropolitan Museum of Art in New York City; a member of the Board of Directors of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher; and a member on the Harvard Medical School Board of Fellows.
Tony was educated at Johns Hopkins University, and earned a medical degree from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.